Motion Sickness: Current Pharmacological Treatment Strategies and the Emerging Role of Tradipitant
Quality in Sport · 08.08.2026 · 66 · 74121
DOI: 10.12775/qs.2026.66.74121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Quality in Sport, online erschienen am 08.08.2026. Verfasst von Karol Jackowiak und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
Motion sickness is a prevalent clinical syndrome triggered by sensory conflict, causing severe autonomic distress. While legacy treatments (anticholinergics and antihistamines) effectively manage symptoms, they cause a debilitating "pharmacological hangover" characterized by severe sedation and cognitive impairment.
Aim
This review evaluates tradipitant, a selective neurokinin-1 (NK1) receptor antagonist, investigating if targeting the Substance P pathway provides robust emetic protection without the functional decline of traditional therapies. Material and methods. A narrative review of PubMed, Google Scholar, Embase, ClinicalTrials, and FDA databases was conducted to analyze tradipitant's pharmacology, efficacy, and safety, emphasizing Phase 2 (Motion Sifnos) and Phase 3 (Motion Syros, Serifos) trials.
Results
Tradipitant competitively inhibits Substance P in brainstem emetic centers without binding to histaminergic or cholinergic receptors. Sifnos data demonstrated a 78% relative risk reduction in vomiting during rough seas. Syros confirmed significant reductions in primary and repeated vomiting across varying sea intensities. Somnolence rates remained low (6–12%), successfully decoupling anti-emetic protection from cognitive impairment, though mild-to-moderate nausea sometimes persisted.
Conclusions
Representing the first major motion sickness advancement in 40 years, tradipitant’s targeted, non-sedating profile preserves physical comfort and cognitive clarity. It addresses a critical unmet need for travelers, though further multi-environment research is warranted.
Zitieren
APA
Jackowiak, K., Kalisiak, M., Kasznicki, M., Czechowska, M., Micek, N., Rogozińska, A., Łącki, J., Skrzypek, E., Kamela, M., & Beśka, W. (2026). Motion Sickness: Current Pharmacological Treatment Strategies and the Emerging Role of Tradipitant. Quality in Sport, 66, 74121. https://doi.org/10.12775/qs.2026.66.74121
Vancouver
Jackowiak K, Kalisiak M, Kasznicki M, Czechowska M, Micek N, Rogozińska A, et al. Motion Sickness: Current Pharmacological Treatment Strategies and the Emerging Role of Tradipitant. Quality in Sport. 2026;66:74121. doi:10.12775/qs.2026.66.74121
BibTeX
@article{Jackowiak2026,
author = {Jackowiak, Karol and Kalisiak, Michał and Kasznicki, Michał and Czechowska, Małgorzata and Micek, Natalia and Rogozińska, Alicja and Łącki, Jakub and Skrzypek, Emilia and Kamela, Mikołaj and Beśka, Wiktor},
title = {Motion Sickness: Current Pharmacological Treatment Strategies and the Emerging Role of Tradipitant},
journal = {Quality in Sport},
year = {2026},
volume = {66},
pages = {74121},
doi = {10.12775/qs.2026.66.74121}
}
EUVIMED